Nestle acquires Aimmune Therapeutics inc.

Aimmune Therapeutics Inc. a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, announced that it has entered into a definitive agreement for Sociétés des Produits Nestlé, S.A. to acquire Aimmune for $34.50 per share in an all-cash transaction, implying a fully-diluted equity value of $2.6 billion. Sociétés des Produits Nestlé, S.A. is a part of Nestlé Health Science (NHSc) and a wholly owned subsidiary of Nestlé S.A. The agreement was unanimously approved by all of the independent members of the Board of Directors of Aimmune. Greg Behar, CEO of Nestlé Health Sciences and an Aimmune Director, abstained due to his position with Nestlé Health Science.Aimmune has recently received FDA approval for Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] the world’s first approved treatment for peanut allergy.